MGTXHealthcare · BiotechnologyThe 7 Wall Street analysts covering Meiragtx Holdings plc hold a median 12-month price target of $27 — +99.7% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 80 of 100 as at 15 Aug 2026 — inside the top quartile. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores Meiragtx Holdings plc on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Growth (99): Sales and profits are climbing, and climbing faster than before.
Accruals (12): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on MGTX, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +99.7% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 14 Aug 2026 | RBC Capital | Maintains | Outperform | $26 → $27 |
| 8 July 2026 | HC Wainwright & Co. | Reiterates | Buy | $20 |
| 8 July 2026 | RBC Capital | Maintains | Outperform | $25 → $26 |
| 15 May 2026 | RBC Capital | Maintains | Outperform | — |
| 22 Apr 2026 | Piper Sandler | Maintains | Overweight | — |
| 17 Apr 2026 | RBC Capital | Maintains | Outperform | — |
| 1 Apr 2026 | Evercore ISI Group | Maintains | Outperform | — |
| 27 Mar 2026 | B of A Securities | Maintains | Buy | — |
| 27 Mar 2026 | Chardan Capital | Maintains | Buy | — |
| 27 Mar 2026 | Piper Sandler | Maintains | Overweight | — |
| 24 Nov 2025 | HC Wainwright & Co. | Initiates | Buy | — |
| 14 Nov 2025 | Chardan Capital | Maintains | Buy | — |
| 14 Nov 2025 | RBC Capital | Maintains | Outperform | — |
| 11 Nov 2025 | Chardan Capital | Maintains | Buy | — |
| 11 Nov 2025 | Piper Sandler | Maintains | Overweight | — |
| 21 Oct 2025 | Raymond James | Initiates | Strong Buy | — |
| 15 Aug 2025 | Chardan Capital | Maintains | Buy | — |
| 14 May 2025 | Chardan Capital | Maintains | Buy | — |
| 17 Mar 2025 | RBC Capital | Maintains | Outperform | — |
| 24 Feb 2025 | Chardan Capital | Maintains | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. MGTX appears on the weeks it earns a place.
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 46% of US stocks
Cheaper than 39% of US stocks
Cheaper than 18% of US stocks
Cheaper than 50% of US stocks
Higher than 99% of US stocks
Higher than 4% of US stocks
Higher than 38% of US stocks
Higher than 99% of US stocks
Higher than 82% of US stocks
Higher than 95% of US stocks
Higher than 99% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Meiragtx Holdings plc — and when they’d sell — is the membership. See the Ticker Nerd 20 →
MeiraGTx Holdings reported Q2 earnings of $1.71 per share, beating the Zacks Consensus Estimate of a loss of $0.39 per share. This compares to a loss of $0.48 per share in the year-ago quarter.
Why it matters — A MGTX watcher would care because the company significantly exceeded analyst earnings expectations and improved sharply versus the prior-year loss.
MeiraGTx reported second quarter 2026 financial and operational results, announcing FDA Breakthrough Therapy Designation and positive three-year Phase 1 data for AAV2-hAQP1, the completed $25 million acquisition of bota-vec from Johnson & Johnson for XLRP, a $100 million equity financing, and an up to $400 million strategic investment from Oberland Capital. The company stated it anticipates global regulatory filings for bota-vec in 2026 and a potential BLA filing for AAV2-hAQP1 in mid-2027.
Why it matters — The quarter marks key clinical and regulatory progress toward commercialization, with breakthrough designation for AAV2-hAQP1, the finalised bota-vec acquisition, and additional financing to support development of both programmes.
Graviton BioScience announced that the U.S. FDA cleared its Investigational New Drug (IND) application on August 7, 2026, for GV101, a novel capsule formulation with improved pharmacokinetics and oral availability, intended for the treatment of Friedreich's ataxia. The clearance advances this formulation toward human trials.
Why it matters — This IND clearance signals progress by a company developing Friedreich's ataxia treatments, a therapeutic area relevant to Meiragtx Holdings plc watchers given the company's focus on Friedreich's ataxia therapy development.
MeiraGTx announced that its Compensation Committee approved equity awards under the company's 2026 Employment Inducement Award Plan to a new employee. The inducement grant was made in accordance with Nasdaq Listing Rule 5635(c)(4) to encourage the new employee to join the company.
Why it matters — MGTX watchers would note this as a routine corporate governance disclosure signaling new hiring supported by equity-based incentives, an administration detail rather than a business development event.
Seeking Alpha highlighted MeiraGTx Holdings' potential for significant upside, driven by late-stage gene therapy assets targeting high-unmet-need indications, including AAV2-hAQP1 for radiation-induced xerostomia with no direct competition, as well as pipeline optionality from GAD for Parkinson's, bota-vec for XLRP, milestone payments, and the Riboswitch platform.
Why it matters — A MeiraGTx watcher would care because the article points to the company's late-stage pipeline and potential catalysts, including pivotal Phase 2 data expected in 2Q27 for its lead xerostomia asset.
The 7 Wall Street analysts covering Meiragtx Holdings plc have a median 12-month price target of $27, with estimates ranging from $19 to $50. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 7 analysts covering Meiragtx Holdings plc, 7 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Meiragtx Holdings plc 80 out of 100 across roughly 4,600 US stocks as at 15 Aug 2026. None of this is personal advice — it does not consider your circumstances.
As at 15 Aug 2026, Meiragtx Holdings plc ranks 80 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (99 of 100).
No one can know that. What the data says: the median 12-month target from 7 analysts implies +99.7% from the last close, and Ticker Nerd's factor model ranks Meiragtx Holdings plc 80 out of 100 as at 15 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Meiragtx Holdings plc publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for MGTX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $19 to $50 over the next 12 months.
Meiragtx Holdings plc returned +62.3% over the 12 months to 14 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
MeiraGTx Holdings plc is a clinical-stage gene therapy company focused on developing novel treatments for serious diseases. The company's primary aim is to harness the transformative potential of gene therapy to address otherwise unmet medical needs.
The most recent item we track (Zacks Investment Research, 13 Aug 2026): "MeiraGTx Holdings PLC (MGTX) Q2 Earnings and Revenues Surpass Estimates". MeiraGTx Holdings reported Q2 earnings of $1.71 per share, beating the Zacks Consensus Estimate of a loss of $0.39 per share. This compares to a loss of $0.48 per share in the year-ago quarter.
MeiraGTx Holdings plc is a clinical-stage gene therapy company focused on developing novel treatments for serious diseases. The company's primary aim is to harness the transformative potential of gene therapy to address otherwise unmet medical needs. MeiraGTx's pipeline includes programs that target genetic disorders, specifically ocular diseases, neurodegenerative conditions, and other systemic diseases. By leveraging proprietary technology platforms, MeiraGTx seeks to deliver long-lasting therapeutic solutions through gene expression modification and regulation. Industrial scalability and technological innovation position MeiraGTx within the biotechnology and pharmaceuticals sectors, drawing significant attention for its potential contributions to medical advances. With a robust scientific foundation and strategic partnerships, particularly in manufacturing and research collaborations, MeiraGTx plays a crucial role in the evolving landscape of personalized medicine. The company's work not only has implications for patients directly affected by genetic disorders but also for broader therapeutic avenues, underscoring the significant impact gene therapy can have across various medical fields.
CEO Dr. Alexandria Forbes Ph.D. · 393 employees · United States · https://www.meiragtx.com